查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529693

北美生物技术和製药服务外包市场规模、份额和趋势分析报告：按服务、最终用途、国家和细分市场预测，2024-2030 年

North America Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End Use, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

北美生物技术和製药服务外包市场成长和趋势：

Grand View Research, Inc.最新报告显示，到2030年，北美生物技术和医药服务外包市场规模预计将达到168.1亿美元，2024年至2030年复合年增长率为5.13%。

将具有更高投资回报率的新分子推向市场的竞争日益激烈，预计将增加全球对 CRO服务供应商的需求。製药公司面临着不断增加的研究成本和监管复杂性，产生了对跨多个产品组合的专业知识的需求，并增加了市场外包的需求。随着临床试验日益私有化，为了专注于核心功能，外包给 CRO 和 CDMO 的情况正在增加。製药和生技公司开始外包需要复杂且严格的进度管理的研发业务。 CRO 的功能是按照客户指定的时间表将新产品推向市场。 CRO 拥有必要的基础设施和熟练的专业知识，并具有与成本、时间和效率相关的多种优势。成本节省有助于为申办者和患者提供最佳的节省。

药物发现和开发是製药和生物技术公司采用的基本策略。慢性和长期疾病的增加导致药物开发过程中对广泛研发投资的需求增加。临床试验失败率的增加，加上药物开发成本的增加，导致製造商遭受重大收益损失。临床试验受挫导致中小型药厂破产。许多私人公司决定，如果他们扰乱开发新药过程，他们将不再获得创投支持。为了避免这种情况并获得可观的投资收益，製药公司现在正在采用基于计算生物学的预测模型，而不是传统的临床试验方法，以提高预计促进成长的市场表现。从专家、研发主管和临床专家那里获得的见解可以帮助公司节省大量可用于研发的资金，从而推动对咨询服务的需求。

医疗保健外包产业近期併购活动迅速增加。该领域的快速成长和广泛的潜力吸引了製药公司、生物技术公司和创业投资的大量投资。因此，公司希望透过策略性收购来扩大其产品组合和能力，并利用新的商机来增强其在市场上的竞争力。例如，2024 年 5 月，Sartorius AG 宣布与 NVIDIA 合作，利用 NVIDIA 的 AI 驱动的计算软体和平台支援新治疗方法的开发。此外，与开发疗法相关的复杂性和高成本导致了产业内合作和整合的增加。併购可以为公司提供互补的技术、专业知识和资源，使他们能够克服开发挑战，缩短产品开发时间并增强製造能力。

北美生物技术和製药服务外包市场报告亮点

  • 按服务划分，咨询业在 2023 年收益占有率最大。该行业的显着增长是由于越来越多地采用咨询服务来满足监管合规、品质保证、改进问题和赞助商的策略咨询要求。此外，製药和生物技术公司面临的主要挑战，例如诈欺案例增加、智慧财产权（IPR）衝突和技术创新不断增加，导致监管咨询服务的广泛使用。推动咨询服务需求的另一个因素是市场整合，导致合资企业、收购和合併的增加。这些因素预计将推动市场成长。
  • 根据最终用途，製药公司部门在 2023 年占据最大收益占有率，超过 57.79%。製药公司越来越倾向于将临床试验、资料管理、监管合规和製造等非核心业务外包给 CRO 和 CMO，预计将推动该领域的收益成长。与维持大量的内部能力相比，外包给 CRO 或 CMO 为製药公司提供了一个具有成本效益的解决方案。
  • 在生技和医药服务外包市场，2023年美国将占87.37%的份额。该国的收益成长是由临床试验的高研发费用推动的，这也是预计推动市场成长的关键因素。例如，2021 年 10 月，美国FDA核准了11 项新的临床试验研究，在未来四年内筹集了超过 2,500 万美元的资金。这些津贴旨在支持专门用于治疗罕见疾病的新医疗产品的开发。这些公司的不断增加扩大了生产能力，以满足不断增长的药品需求，预计将推动市场成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章北美生物技术和製药服务外包市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
  • 技术景观
  • 定价模式分析
  • GxP 概述
  • 临床试验量分析（2023）
  • 研发投入分析
  • 北美生技与製药服务外包市场分析工具
  • COVID-19 影响分析

第四章北美生物技术和製药服务外包市场：按服务分类的估计和趋势分析

  • 细分仪表板
  • 北美生物技术和製药服务外包市场：按服务分类的变化分析
  • 2018-2030 年北美生技及製药服务外包市场规模及趋势分析（依服务）
  • 咨询
  • 监管业务
  • 产品设计与开发
  • 审核与评估
  • 产品维护
  • 培训和教育
  • 其他的

第五章北美生物技术和製药服务外包市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 北美生物技术和製药服务外包市场：最终用途的变化分析
  • 2018-2030 年北美生物技术和製药服务外包市场规模和趋势分析（按最终用途）
  • 製药公司
  • 生技公司

第六章北美生物技术和製药服务外包市场：按国家、服务、最终用途分类的估计和趋势分析

  • 国家仪表板
  • 北美生物技术和製药服务外包市场：国家差异分析
  • 美国
  • 加拿大
  • 墨西哥
  • 波多黎各

第七章 竞争格局

  • 公司分类
    • 市场领导
    • 新兴企业
  • 2023 年企业市场占有率/估值分析
  • 服务热图分析
  • 公司简介
    • Parexel International Corporation
    • The Quantic Group
    • IQVIA
    • Lachman Consultant Services, Inc.
    • GMP Pharmaceuticals Pty Ltd.
    • LabCorp
    • Charles River Laboratories
    • ICON plc.
    • Syneos Health
    • Lonza
    • Catalent Inc.
    • Samsung Biologics
Product Code: GVR-4-68040-330-1

North America Biotechnology and Pharmaceutical Services Outsourcing Market Growth & Trends:

The North America biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 16.81 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 5.13% from 2024 to 2030.

Increasing competition to launch novel molecules with better RoI is expected to heighten the demand for CRO service providers across the globe. Pharmaceutical companies face complexity in regulations along with increased research costs, creating a need for expertise in numerous portfolios and driving the need for outsourcing in the market. With increasing clinical trial privatization, there has been an increase in outsourcing functions to CROs and CDMOs to focus on core capabilities. Pharmaceutical and biotechnology companies have started outsourcing R&D activities, which are complex and need a strict timeline to follow up. A CRO's function is to bring new products to the market as per the timeline given by the client. CROs have the required infrastructure and skilled expertise, which provides several advantages associated with cost, time, and efficiency. The cost saved helps in offering the best savings for sponsors and patients.

Drug discovery and development is an integral strategy adopted by pharmaceutical and biotechnology companies. An increase in the prevalence of chronic and long-term diseases led to a rise in the demand for extensive R&D investments in the drug development process. Growing clinical trial failure rates coupled with increasing drug development costs lead to huge losses in revenue for manufacturers. Setbacks faced in clinical studies have led smaller pharmaceutical companies to go bankrupt. Many private investors have been observed to withdraw venture capital support from startup drug companies, considering their investments would suffer if there were a disruption in the drug development process. To circumvent these situations and gain a substantial return on investment, pharmaceutical companies are now adopting computational biology-based predictive models over traditional methods of clinical trials, which are expected to drive market growth during the forecast period. Insights gained from subject-matter experts, R&D executives, and clinical professionals help a company save a large amount, which can be spent on R&D, thereby boosting demand for consulting services.

The healthcare outsourcing industry has recently witnessed a surge in mergers and acquisitions. The sector's rapid growth and promising potential have attracted significant investment from pharmaceutical companies, biotech firms, & venture capitalists. As a result, companies seek to expand their portfolios and capabilities through strategic acquisitions to capitalize on emerging opportunities and strengthen their competitive position in the market. For instance, in May 2024, Sartorius AG announced a collaboration with NVIDIA to help the development of new therapies, leveraging NVIDIA's AI-powered computing software and platform. Moreover, the complexity and high costs associated with developing therapeutics are leading to increased collaboration & consolidation within the industry. Mergers & acquisitions offer companies complementary technologies, expertise, and resources, enabling them to overcome development challenges, accelerate product development timelines, and enhance manufacturing capabilities.

North America Biotechnology And Pharmaceutical Services Outsourcing Market Report highlights

  • Based on service, the consulting segment held the largest revenue share in 2023. The large segment growth is owing to the growing adoption of consulting services to meet regulatory compliance, quality assurance, remediation challenges, and strategic consulting requirements by sponsors. Furthermore, regulatory consulting services are widely used owing to increasing fraud cases, discrepancies in Intellectual Property Rights (IPR), and rising technological innovation, which are some of the major challenges faced by pharmaceutical and biotechnology companies. Another factor driving the demand for consulting services is the consolidated nature of the market, which leads to an increase in the number of joint ventures, takeovers, acquisitions, and mergers. Such factors are anticipated to drive the market growth.
  • Based on end use, the pharmaceutical companies segment held the largest revenue share of over 57.79% in 2023. The segment growth is owing to an increasing preference for outsourcing non-core activities such as clinical trials, data management, regulatory compliance, and manufacturing to CROs and CMOs among pharmaceutical companies is anticipated to boost segment revenue growth. Outsourcing to CROs and CMOs provides pharmaceutical companies with cost-effective solutions compared to maintaining extensive in-house capabilities.
  • The U.S. dominated the biotechnology and pharmaceutical services outsourcing market with a share of 87.37% in 2023. The country's revenue growth is owing to high R&D spending on clinical trials, which is another major factor expected to fuel market growth. For instance, in October 2021, the U.S. FDA approved 11 new clinical trial research, resulting in over USD 25 million in funding over the next four years. These grants aim to support the development of new medical products specifically for treating rare diseases. The growing presence of these companies expanding their manufacturing capabilities to cater to the rising demand for pharmaceuticals is anticipated to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Details of primary research
  • 1.6. Market Formulation & Validation
  • 1.7. Country-wise Market Calculation
    • 1.7.1. Country Wise Market: Base Estimates
    • 1.7.2. CAGR Calculation
    • 1.7.3. Country Based Segment Share Calculation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
    • 1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
    • 1.8.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.8.4. Bottom-up Approach (Model 4)
  • 1.9. Research Scope and Assumptions
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. List of Abbreviations
  • 1.13. Objectives
    • 1.13.1. Objective 1
    • 1.13.2. Objective 2
    • 1.13.3. Objective 3
    • 1.13.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Outsourcing of R&D Activities
      • 3.2.1.2. Changing Regulatory Landscape
      • 3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
      • 3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
      • 3.2.1.5. Increasing Mergers and Collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring Issues and Lack of Standardization
      • 3.2.2.2. Loss of Control
      • 3.2.2.3. Data Security Issues
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. GxP Overview
    • 3.5.1. Good Manufacturing Practices (GMP)
    • 3.5.2. Current Good Manufacturing Practices (cGMP)
    • 3.5.3. Good Laboratory Practices (GLP)
    • 3.5.4. Good Clinical Practices (GCP)
    • 3.5.5. Good Distribution Practices (GDP)
  • 3.6. Clinical Trials Volume Analysis (2023)
    • 3.6.1. Total Number of Clinical Trials, by Country
    • 3.6.2. Total Number of Clinical Trials, by Phase
    • 3.6.3. Total Number of Clinical Trials, by Study Design
    • 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area
  • 3.7. R&D Investment Analysis
  • 3.8. North America Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.8.1. Porter's Five Forces Analysis
    • 3.8.2. PESTEL Analysis
  • 3.9. COVID-19 Impact Analysis

Chapter 4. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
  • 4.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Consulting
    • 4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Regulatory Consulting
      • 4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Clinical Development Consulting
      • 4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Strategic Planning & Business Development Consulting
      • 4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Quality Management Systems Consulting
      • 4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory Affairs
    • 4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Legal Representation
      • 4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Regulatory Writing & Publishing
      • 4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Product Registration & Clinical Trial Applications
      • 4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Regulatory Submissions
      • 4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.6. Regulatory Operations
      • 4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Design & Development
    • 4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Research, Strategy, & Concept Generation
      • 4.6.2.1. Research, Strategy, & Concept Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Concept & Requirements Development
      • 4.6.3.1. Concept & Requirements Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Detailed Design & Process Development
      • 4.6.4.1. Detailed Design & Process Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Design Verification & Validation
      • 4.6.5.1. Design Verification & Validation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.6. Process Validation & Manufacturing Transfer
      • 4.6.6.1. Process Validation & Manufacturing Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.7. Production & Commercial Support
      • 4.6.7.1. Production & Commercial Support Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Auditing and Assessment
    • 4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.2. General Auditing
      • 4.7.2.1. General Auditing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.3. Gap Assessments
      • 4.7.3.1. Gap Assessments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.4. Due Diligence Assessments
      • 4.7.4.1. Due Diligence Assessments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.5. Mock Audits/Inspections
      • 4.7.5.1. Mock Audits/Inspections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.6. Inspection/Audit Management and Support
      • 4.7.6.1. Inspection/Audit Management and Support Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.7. Others
      • 4.7.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Maintenance
    • 4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
  • 5.3. North America Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biotech Companies
    • 5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Estimates & Trend Analysis, by Service, by End-Use

  • 6.1. Country Dashboard
  • 6.2. North America Biotechnology and Pharmaceutical Services Outsourcing Market: Country Movement Analysis
  • 6.3. U.S.
    • 6.3.1. Key Country Dynamics
    • 6.3.2. Competitive Scenario
    • 6.3.3. Regulatory Framework
    • 6.3.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Canada
    • 6.4.1. Key Country Dynamics
    • 6.4.2. Competitive Scenario
    • 6.4.3. Regulatory Framework
    • 6.4.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Mexico
    • 6.5.1. Key Country Dynamics
    • 6.5.2. Competitive Scenario
    • 6.5.3. Regulatory Framework
    • 6.5.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Puerto Rico
    • 6.6.1. Key Country Dynamics
    • 6.6.2. Competitive Scenario
    • 6.6.3. Regulatory Framework
    • 6.6.4. Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2023
  • 7.3. Service Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Parexel International Corporation
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Service Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. The Quantic Group
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Service Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. IQVIA
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Service Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Service Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals Pty Ltd.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Service Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. LabCorp
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Service Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Charles River Laboratories
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Service Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. ICON plc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Service Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Syneos Health
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Service Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Lonza
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Service Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Catalent Inc.
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Service Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. Samsung Biologics
      • 7.4.12.1. Company Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Service Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 4 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 5 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 6 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 7 North America Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 8 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018 - 2030 (USD Million)
  • Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 15 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 20 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 21 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 25 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 26 Canada Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 27 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 28 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 29 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 30 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 31 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 32 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 33 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 34 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 35 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 36 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 37 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by Auditing and Assessment, 2018 - 2030 (USD Million)
  • Table 38 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 North America Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 North America Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
  • Fig. 13 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 14 North America Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 15 North America Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 16 North America Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
  • Fig. 17 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
  • Fig. 19 North America Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 20 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 21 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 22 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 23 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 24 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
  • Fig. 26 North America Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
  • Fig. 27 North America Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
  • Fig. 28 North America Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
  • Fig. 29 North America Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation, 2018 - 2030 (USD Million)
  • Fig. 30 North America Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer, 2018 - 2030 (USD Million)
  • Fig. 31 North America Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
  • Fig. 32 North America Biotechnology and Pharmaceutical Services Outsourcing, for Auditing and Assessment, 2018 - 2030 (USD Million)
  • Fig. 33 North America Biotechnology and Pharmaceutical Services Outsourcing, for General Auditing, 2018 - 2030 (USD Million)
  • Fig. 34 North America Biotechnology and Pharmaceutical Services Outsourcing, for Gap Assessments, 2018 - 2030 (USD Million)
  • Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing, for Due Diligence Assessments, 2018 - 2030 (USD Million)
  • Fig. 36 North America Biotechnology and Pharmaceutical Services Outsourcing, for Mock Audits/Inspections, 2018 - 2030 (USD Million)
  • Fig. 37 North America Biotechnology and Pharmaceutical Services Outsourcing, for Inspection/Audit Management and Support, 2018 - 2030 (USD Million)
  • Fig. 38 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 39 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Maintenance, 2018 - 2030 (USD Million)
  • Fig. 40 North America Biotechnology and Pharmaceutical Services Outsourcing, for Training & Education, 2018 - 2030 (USD Million)
  • Fig. 41 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 42 North America Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 43 North America Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 44 Country Outlook, 2023 & 2030
  • Fig. 45 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)